Current Headlines

  1. Protagen AG Signs Collaboration With QIAGEN To Develop Novel Protein Based Companion Diagnostics For Autoimmune Therapies
    11/17/2014

    Protagen AG recently announced that it has entered into a long-term collaboration agreement with QIAGEN targeting the development of novel protein-based companion diagnostics for autoimmune disorders.

  2. Milk: A Novel Delivery System For Pediatric HIV Drugs
    11/14/2014

    Scientists at Penn State have developed a method of altering proteins in milk so that they bind with antiretroviral drugs. 

  3. New Research Paves Way For E. Coli Vaccine
    11/14/2014

    An international team of researchers have found that various strains of the E.coli bacteria from around the world have several key similarities that can be exploited for preparing a global vaccine to fight this often fatal infection.

  4. Biogen Idec Shells Out $10 M Milestone To Isis For New Investigational Drug R&D
    11/14/2014

    Biogen Idec paid Isis Pharmaceuticals a $10 million milestone payment after the launch of studies to support an Investigation New Drug application (IND) for its neurodegenerative disease treatment, ISIS-BIIB3 Rx.

  5. RedHill BioPharma’s H. Pylori Drug Snags FDA QIDP Status
    11/14/2014

    RedHill BioPharma, an Israeli firm specializing on late clinical-stage drugs for gastrointestinal and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) status for RHB-105, its Phase 3 Helicobacter pylori (H. pylori) eradication therapy.

  6. GliaCure’s Lead Drug For Alzheimer’s Fast Tracked By FDA
    11/14/2014

    GliaCure, a privately-held biotech firm that develops treatments for neurological and neuropsychiatric disorders based on glial targets, announced that the U.S. Food and Drug Administration (FDA) has awarded Fast Track status to its lead drug GC021109 as treatment for Alzheimer’s disease.

  7. FDA Grants Breakthrough Therapy Designation To Spark Therapeutics’ SPK-RPE65 For Retinal Dystrophies
    11/13/2014

    Spark Therapeutics announced in a press release that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its lead candidate, SPK-RPE65.

  8. FDA Accepts Amgen's BLA For Evolocumab In High Cholesterol
    11/13/2014

    Amgen states that the Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for evolocumab.

  9. Gonorrhea Joins List Of Increasingly Antibiotic-Resistant Infections
    11/13/2014

    Public Health England released a report which found that gonorrhea was building resistance to traditional antibiotic treatment, The Pharmaceutical Journal reports.

  10. Discovery Of Anti-Typhoid Gene May Lead To Improved Typhoid Vaccines
    11/13/2014

    Researchers at the University of Melbourne have identified a gene that provides a natural resistance against typhoid fever, and persons carrying this gene variant have a nearly five-fold protection against the serious infectious disease.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.